ABSTRACT
The novel coronavirus disease 2019 (COVID-19) has been the biggest public health problem of the present world. As the number of people suffering from the pandemic is rising, it is likely to claim more life and worsen the global health and economy. Nepal, one of the developing countries in the south Asia has been strongly influenced by the pandemic and struggling to contain it with multiple interventions, however, spatiotemporal dynamics of the epidemic and its linkage with various intervention strategies has not been studied yet. Here, we employed the prospective spatial-temporal analysis with SaTScan assessing dynamics of the COVID-19 cases from 23 January to 31 August 2020 at district level in Nepal. The results revealed that COVID-19 dynamics in the early stage of transmission was slower and confined in certain districts. However, from the third week of April, transmission spread rapidly across districts of Province No. 2 and Sudoorpaschim Province, primarily introduced by Nepalese citizens returning from India. Despite nationwide lockdown, nine statistically significant active and emerging clusters were detected between 23 January and 21 July 2020, whereas ten emerging clusters were observed for extended period to 31 August. The population density and population inflow from India crossing the sealed border had significant effects on the elevated risk of the epidemic. The capital city Kathmandu has become the highest-risk active cluster since August when travel restriction has been suspended. Movement restriction appears to be the most effective non-pharmaceutical intervention against the COVID-19 for resource-scarce countries with limited health care facilities. Our findings could be valuable to the health authorities within Nepal and beyond to better allocate resources and improve interventions on the pandemic for containing it efficiently.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Natural Science Foundation of China (82041021).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the manuscript are freely available.
